{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:36:14Z","timestamp":1769445374432,"version":"3.49.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Science Basic Research Program of Shaanxi","award":["2017ZDJC-11"],"award-info":[{"award-number":["2017ZDJC-11"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both hyperthermic intraperitoneal chemotherapy (HIPEC) and conventional intraperitoneal chemotherapy (IP) have shown survival benefits in ovarian cancer (OC), but direct comparisons between the two perfusion modalities are lacking. This study aimed to compare effectiveness and safety between HIPEC and conventional IP in OC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective real-world study analyzed 606 patients with stages II-IV OC who received HIPEC or IP following cytoreductive surgery between 2013 and 2024. The primary endpoint was progression-free survival. Overall survival and adverse events were secondary endpoints. The study used inverse probability of treatment propensity-score weighting. We also conducted sensitivity analyses to evaluate result robustness and subgroup analyses to explore potential effect modification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After a median follow-up of 26\u2009months, disease progression occurred in 40.6% of patients in the HIPEC group and 55.0% in the IP group (hazard ratio [HR] 0.79; P\u2009=\u2009.103). Mortality rates were 13.2% and 22.5%, respectively (HR 0.83; P\u2009=\u2009.434), showing no significant differences in progression and survival between the two groups. Exploratory subgroup analyses suggested a trend toward improved progression-free outcomes with HIPEC, particularly among patients with BRCA wild-type or BRCA1-mutated tumors and early postoperative perfusion. Hypoalbuminemia was the most common event in both groups (HIPEC 27.2%; IP 15.6%). HIPEC group had more abdominal distension and wound dehiscence, whereas IP patients experienced nausea and rash more frequently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HIPEC did not significantly improve survival over conventional IP in the overall population, but showed greater benefit in specific subgroups, underscoring the importance of individualized intraperitoneal chemotherapy strategies in OC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf424","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:02:16Z","timestamp":1766062936000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of hyperthermic intraperitoneal chemotherapy and intraperitoneal chemotherapy in ovarian cancer"],"prefix":"10.1093","volume":"31","author":[{"given":"Siyi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9084-1576","authenticated-orcid":false,"given":"Qian","family":"Qie","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaling","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Xi\u2019an Jiaotong University Health Science Center , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-4456","authenticated-orcid":false,"given":"Qiling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061, People\u2019s Republic of","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2026012601220579100_oyaf424-B1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"2026012601220579100_oyaf424-B2","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"2026012601220579100_oyaf424-B3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"2026012601220579100_oyaf424-B4","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"2026012601220579100_oyaf424-B5","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent."},{"key":"2026012601220579100_oyaf424-B6","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"2026012601220579100_oyaf424-B7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","article-title":"Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review","volume":"7","author":"van Stein","year":"2021","journal-title":"JAMA Oncol."},{"key":"2026012601220579100_oyaf424-B8","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol."},{"key":"2026012601220579100_oyaf424-B9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med."},{"key":"2026012601220579100_oyaf424-B10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1525-1438.2007.01100.x","article-title":"National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer","volume":"18","author":"Trimble","year":"2008","journal-title":"Int J Gynecol Cancer."},{"key":"2026012601220579100_oyaf424-B11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2006.08.020","article-title":"Intraperitoneal chemotherapy and the NCI clinical announcement","volume":"103","author":"Trimble","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2026012601220579100_oyaf424-B12","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med."},{"key":"2026012601220579100_oyaf424-B13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol."},{"key":"2026012601220579100_oyaf424-B14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/01.ogx.0000228777.15365.32","article-title":"Intraperitoneal chemotherapy for epithelial ovarian cancer","volume":"61","author":"Alhayki","year":"2006","journal-title":"Obstet Gynecol Surv"},{"key":"2026012601220579100_oyaf424-B15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med."},{"key":"2026012601220579100_oyaf424-B16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence","volume":"7","author":"Ceelen","year":"2010","journal-title":"Nat Rev Clin Oncol."},{"key":"2026012601220579100_oyaf424-B17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and Eastern cooperative oncology group","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol."},{"key":"2026012601220579100_oyaf424-B18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","article-title":"Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines","volume":"34","author":"van de Vaart","year":"1998","journal-title":"Eur J Cancer."},{"key":"2026012601220579100_oyaf424-B19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int J Cancer."},{"key":"2026012601220579100_oyaf424-B20","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/bjc.1997.297","article-title":"Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells","volume":"75","author":"Hettinga","year":"1997","journal-title":"Br J Cancer."},{"key":"2026012601220579100_oyaf424-B21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/02656739709023545","article-title":"Reduction of cellular cisplatin resistance by hyperthermia\u2014a review","volume":"13","author":"Hettinga","year":"1997","journal-title":"Int J Hyperthermia."},{"key":"2026012601220579100_oyaf424-B22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ygyno.2022.10.010","article-title":"Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a meta-analysis","volume":"167","author":"Kim","year":"2022","journal-title":"Gynecol Oncol."},{"key":"2026012601220579100_oyaf424-B23","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/ijc.34219","article-title":"Reply to: comments on \u201ceffect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial\u201d","volume":"151","author":"Koole","year":"2022","journal-title":"Int J Cancer."},{"key":"2026012601220579100_oyaf424-B24","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ijc.34124","article-title":"Effect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial","volume":"151","author":"Koole","year":"2022","journal-title":"Int J Cancer."},{"key":"2026012601220579100_oyaf424-B25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF00686037","article-title":"Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells","volume":"34","author":"Ohno","year":"1994","journal-title":"Cancer Chemother Pharmacol."},{"key":"2026012601220579100_oyaf424-B26","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"2026012601220579100_oyaf424-B27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026012601220579100_oyaf424-B28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"key":"2026012601220579100_oyaf424-B29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN guidelines insights: ovarian cancer, version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"key":"2026012601220579100_oyaf424-B30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol."},{"key":"2026012601220579100_oyaf424-B31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jso.21068","article-title":"The intraoperative staging systems in the management of peritoneal surface malignancy","volume":"98","author":"Portilla","year":"2008","journal-title":"J Surg Oncol."},{"key":"2026012601220579100_oyaf424-B32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"2026012601220579100_oyaf424-B33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer."},{"key":"2026012601220579100_oyaf424-B34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-based direct adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J Am Stat Assoc."},{"key":"2026012601220579100_oyaf424-B35","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/sim.1903","article-title":"Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study","volume":"23","author":"Lunceford","year":"2004","journal-title":"Stat Med."},{"key":"2026012601220579100_oyaf424-B36","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med."},{"key":"2026012601220579100_oyaf424-B37","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med."},{"key":"2026012601220579100_oyaf424-B38","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"2026012601220579100_oyaf424-B39","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet."},{"key":"2026012601220579100_oyaf424-B40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/jcm12031111","article-title":"Comparative survival outcomes of hyperthermic intraperitoneal chemotherapy, intraperitoneal chemotherapy and intravenous chemotherapy for primary advanced ovarian cancer: a network meta-analysis","volume":"12","author":"Tang","year":"2023","journal-title":"J Clin Med."},{"key":"2026012601220579100_oyaf424-B41","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3802\/jgo.2022.33.e1","article-title":"Clinical trial protocol for HyNOVA: hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901\/2020)","volume":"33","author":"Farrell","year":"2022","journal-title":"J Gynecol Oncol."},{"key":"2026012601220579100_oyaf424-B42","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026012601220579100_oyaf424-B43","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1038\/s41467-019-11269-8","article-title":"Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun."},{"key":"2026012601220579100_oyaf424-B44","first-page":"5910","article-title":"Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo","volume":"51","author":"Ning","year":"1991","journal-title":"Cancer Res."},{"key":"2026012601220579100_oyaf424-B45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.addr.2020.03.006","article-title":"A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy","volume":"163-164","author":"van Rhoon","year":"2020","journal-title":"Adv Drug Deliv Rev."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf424\/66033420\/oyaf424.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf424\/66033420\/oyaf424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf424\/66033420\/oyaf424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T06:22:17Z","timestamp":1769408537000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf424\/8384257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf424","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,19]]},"article-number":"oyaf424"}}